Elixiron Immunotherapeutics (TPEx: 7871) announced interim results from its phase 2 study of enrupatinib, an experimental treatment for Alzheimer's disease ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE